Stay updated on Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial
Sign up to get notified when there's something new on the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page.

Latest updates to the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page
- Check3 days agoChange DetectedAdded a new publication citation: Avapritinib improves cutaneous involvement in indolent systemic mastocytosis from the PIONEER study (J Am Acad Dermatol, online ahead of print).SummaryDifference0.0%

- Check10 days agoChange DetectedNew revision tag updated from v3.4.1 to v3.4.2; no other content changes are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check18 days agoChange Detected- Revision: v3.4.1 replaces v3.4.0 on the page.SummaryDifference0.0%

- Check32 days agoChange DetectedAdded a glossary display and updated metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, Revision: v3.4.0). Some labels were removed or changed (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).SummaryDifference0.2%

- Check39 days agoChange DetectedThe page shows a new Revision tag: v3.3.4 replacing v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedAdded a Locations section listing study sites across US states and Canadian provinces. Removed the HHS Vulnerability Disclosure notice and updated the revision tag to v3.3.3.SummaryDifference1%

Stay in the know with updates to Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page.